Interim results from a Phase 1/2 study indicate Johnson & Johnson's SARS-CoV-2 vaccine elicits a long-lasting immune response, Bloomberg reports.
Interim results from a Phase 1/2 study indicate Johnson & Johnson's SARS-CoV-2 vaccine elicits a long-lasting immune response, Bloomberg reports.
...and receive Daily News bulletins.
Already have a GenomeWeb or 360Dx account?
Login Now.
Don't have a GenomeWeb or 360Dx account?
Register for Free.